| Avra Jordano-alter, MD | |
|
59 Ornac, Suite 1, Concord, MA 01742-3317 | |
| (978) 369-7627 | |
| (978) 371-2240 |
| Full Name | Avra Jordano-alter |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 30 Years |
| Location | 59 Ornac, Concord, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104818392 | NPI | - | NPPES |
| 3195759 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 158912 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Emerson Hospital - | W concord, MA | Hospital |
| Entity Name | Concord Ob/gyn Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114919313 PECOS PAC ID: 0941278261 Enrollment ID: O20040923000572 |
News Archive
A new generation of broadly neutralizing antibodies provides a novel approach to treating HIV infection.
In the first study of its kind, researchers at Queens College and Mount Sinai School of Medicine have found that low socioeconomic status (SES) and maternal gestational diabetes together may cause a 14-fold increased risk of attention deficit hyperactivity disorder (ADHD) in six year olds.
In a study that suggests a new frontier in immunology, scientists at the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine (UMDNJ-SOM) report on evidence that shows human blood contains thousands of autoantibodies that bind specifically to antigens from organs and tissues all over the body and act to clear cellular debris that results from injury and disease.
Millions of people in the United States have a circulatory problem of the legs called peripheral vascular disease. It can be painful and may even require surgery in serious cases. This disease can lead to severe skeletal muscle wasting and, in turn, limb amputation.
pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN® for the treatment of Diabetic Macular Edema (DME), today announced that Alimera Sciences, Inc, pSivida's collaborative partner, received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ILUVIEN. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form.
› Verified 8 days ago
| Entity Name | One To One Gyn Westford Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922600931 PECOS PAC ID: 7012320286 Enrollment ID: O20210107000526 |
News Archive
A new generation of broadly neutralizing antibodies provides a novel approach to treating HIV infection.
In the first study of its kind, researchers at Queens College and Mount Sinai School of Medicine have found that low socioeconomic status (SES) and maternal gestational diabetes together may cause a 14-fold increased risk of attention deficit hyperactivity disorder (ADHD) in six year olds.
In a study that suggests a new frontier in immunology, scientists at the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine (UMDNJ-SOM) report on evidence that shows human blood contains thousands of autoantibodies that bind specifically to antigens from organs and tissues all over the body and act to clear cellular debris that results from injury and disease.
Millions of people in the United States have a circulatory problem of the legs called peripheral vascular disease. It can be painful and may even require surgery in serious cases. This disease can lead to severe skeletal muscle wasting and, in turn, limb amputation.
pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN® for the treatment of Diabetic Macular Edema (DME), today announced that Alimera Sciences, Inc, pSivida's collaborative partner, received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ILUVIEN. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Avra Jordano-alter, MD 59 Ornac, Suite 1, Concord, MA 01742-3317 Ph: (978) 369-7627 | Avra Jordano-alter, MD 59 Ornac, Suite 1, Concord, MA 01742-3317 Ph: (978) 369-7627 |
News Archive
A new generation of broadly neutralizing antibodies provides a novel approach to treating HIV infection.
In the first study of its kind, researchers at Queens College and Mount Sinai School of Medicine have found that low socioeconomic status (SES) and maternal gestational diabetes together may cause a 14-fold increased risk of attention deficit hyperactivity disorder (ADHD) in six year olds.
In a study that suggests a new frontier in immunology, scientists at the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine (UMDNJ-SOM) report on evidence that shows human blood contains thousands of autoantibodies that bind specifically to antigens from organs and tissues all over the body and act to clear cellular debris that results from injury and disease.
Millions of people in the United States have a circulatory problem of the legs called peripheral vascular disease. It can be painful and may even require surgery in serious cases. This disease can lead to severe skeletal muscle wasting and, in turn, limb amputation.
pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN® for the treatment of Diabetic Macular Edema (DME), today announced that Alimera Sciences, Inc, pSivida's collaborative partner, received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ILUVIEN. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form.
› Verified 8 days ago
Christina Therese Thomas, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 59 Ornac, #2suite 1, Concord, MA 01742 Phone: 978-369-7627 Fax: 978-371-2240 | |
Dr. Emily Strehle, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 131 Old Road To 9 Acre Cor, Suite 830, Concord, MA 01742 Phone: 978-371-1396 Fax: 978-371-8277 | |
Dr. Jeffrey Riley, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 133 Old Road To 9 Acre Cor, Emerson Hospital, Concord, MA 01742 Phone: 978-287-3502 | |
Ingrid Anita Balcomb, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 131 Old Road To 9 Acre Cor, Suite 830, Concord, MA 01742 Phone: 978-371-1396 Fax: 978-371-8277 | |
Richard D. Rubin, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 59 Ornac, Suite 1, Concord, MA 01742 Phone: 978-369-7627 Fax: 978-371-2240 | |
Dr. Jonathan Emery Grogins, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 131 Old Road To 9 Acre Cor, Suite 830, Concord, MA 01742 Phone: 978-371-1396 Fax: 978-371-8277 |